Brown Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$110M Buy
119,391
+816
+0.7% +$827K 0.18% 99
2025
Q4
$127M Buy
118,575
+102
+0.1% +$97.5K 0.18% 99
2025
Q3
$90.4M Buy
118,473
+9,370
+9% +$6.97M 0.12% 133
2025
Q2
$85M Buy
109,103
+1,122
+1% +$872K 0.11% 131
2025
Q1
$89.2M Buy
107,981
+1,125
+1% +$936K 0.13% 126
2024
Q4
$82.5M Sell
106,856
-2,105
-2% -$1.74M 0.1% 149
2024
Q3
$96.5M Sell
108,961
-1,786
-2% -$1.61M 0.12% 139
2024
Q2
$100M Sell
110,747
-589
-0.5% -$471K 0.13% 127
2024
Q1
$86.6M Sell
111,336
-5,967
-5% -$4.25M 0.12% 151
2023
Q4
$68.4M Sell
117,303
-2,281
-2% -$1.33M 0.1% 161
2023
Q3
$64.2M Sell
119,584
-567
-0.5% -$292K 0.11% 157
2023
Q2
$56.3M Sell
120,151
-2,952
-2% -$1.24M 0.09% 183
2023
Q1
$42.3M Buy
123,103
+5,870
+5% +$1.98M 0.07% 218
2022
Q4
$42.9M Sell
117,233
-1,565
-1% -$555K 0.08% 207
2022
Q3
$38.4M Buy
118,798
+22,215
+23% +$7.04M 0.07% 209
2022
Q2
$31.3M Buy
96,583
+6,816
+8% +$2.05M 0.06% 243
2022
Q1
$25.7M Sell
89,767
-311
-0.3% -$80K 0.04% 286
2021
Q4
$24.9M Buy
90,078
+185
+0.2% +$46.9K 0.03% 296
2021
Q3
$20.8M Sell
89,893
-370
-0.4% -$91.3K 0.03% 294
2021
Q2
$20.7M Sell
90,263
-2,676
-3% -$538K 0.03% 290
2021
Q1
$17.4M Sell
92,939
-6,890
-7% -$1.35M 0.03% 291
2020
Q4
$16.9M Buy
99,829
+437
+0.4% +$65.2K 0.03% 276
2020
Q3
$14.7M Buy
99,392
+2,197
+2% +$340K 0.03% 265
2020
Q2
$16M Buy
97,195
+917
+1% +$141K 0.04% 244
2020
Q1
$13.4M Buy
96,278
+10,740
+13% +$1.48M 0.04% 244
2019
Q4
$11.2M Buy
85,538
+2,529
+3% +$293K 0.03% 313
2019
Q3
$9.28M Buy
83,009
+2,923
+4% +$325K 0.03% 330
2019
Q2
$8.87M Sell
80,086
-18,321
-19% -$2.16M 0.03% 332
2019
Q1
$12.8M Sell
98,407
-12,331
-11% -$1.5M 0.04% 310
2018
Q4
$12.8M Sell
110,738
-48,448
-30% -$5.41M 0.04% 291
2018
Q3
$17.1M Buy
159,186
+313
+0.2% +$31.3K 0.05% 271
2018
Q2
$13.6M Buy
158,873
+22,312
+16% +$1.83M 0.04% 281
2018
Q1
$10.6M Buy
136,561
+54,577
+67% +$4.39M 0.03% 294
2017
Q4
$6.92M Buy
81,984
+4,814
+6% +$410K 0.02% 356
2017
Q3
$6.6M Buy
77,170
+4,301
+6% +$353K 0.02% 354
2017
Q2
$6M Buy
72,869
+1,127
+2% +$91.9K 0.02% 381
2017
Q1
$6.04M Buy
71,742
+419
+0.6% +$33.6K 0.02% 347
2016
Q4
$5.25M Sell
71,323
-3,709
-5% -$276K 0.02% 367
2016
Q3
$6.02M Buy
75,032
+744
+1% +$59.6K 0.02% 345
2016
Q2
$5.85M Sell
74,288
-2,619
-3% -$197K 0.02% 341
2016
Q1
$5.54M Sell
76,907
-1,052
-1% -$79.6K 0.02% 350
2015
Q4
$6.57M Buy
77,959
+4,975
+7% +$413K 0.02% 333
2015
Q3
$6.11M Buy
72,984
+4,386
+6% +$370K 0.02% 331
2015
Q2
$5.73M Sell
68,598
-2,455
-3% -$187K 0.02% 328
2015
Q1
$5.16M Buy
71,053
+858
+1% +$61.1K 0.02% 344
2014
Q4
$4.84M Buy
70,195
+4,082
+6% +$276K 0.02% 351
2014
Q3
$4.29M Buy
66,113
+1,180
+2% +$74.7K 0.01% 355
2014
Q2
$4.04M Sell
64,933
-1,084
-2% -$64.7K 0.01% 356
2014
Q1
$3.89M Sell
66,017
-878
-1% -$49K 0.01% 358
2013
Q4
$3.41M Sell
66,895
-2,800
-4% -$140K 0.01% 364
2013
Q3
$3.51M Sell
69,695
-1,931
-3% -$101K 0.01% 346
2013
Q2
$3.52M Buy
+71,626
New +$3.9M 0.01% 336

Other funds holding LLY

Brown Advisory's LLY Position: Q1 2026 in Review

Brown Advisory increased its Eli Lilly (LLY) stake by 0.69% in Q1 2026, buying an estimated $827K and bringing the position to 119,391 shares worth $110M. The position accounts for 0.18% of the portfolio, ranked #99.

Brown Advisory first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $127M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Brown Advisory held 119,391 shares of Eli Lilly worth $110M as of Q1 2026.
  • Brown Advisory bought 816 Eli Lilly shares in Q1 2026, an estimated $827K.
  • Eli Lilly made up 0.18% of Brown Advisory's portfolio in Q1 2026, its #99 holding.
  • Brown Advisory first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Brown Advisory's Eli Lilly position peaked at $127M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.